Physician profile
Stephane M Counts
NPI 1922356823
$9,380.29
in general payments reported to CMS, 2019-2025
34 companies · $2,789 in 2025
The $2,789 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $811 · 2022: $963 · 2023: $1,727 · 2024: $3,091 · 2025: $2,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,601 · Education: $6.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,600.95 |
| Education | $6.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,815.65 | 2023-2025 | Biktarvy, Sunlenca |
| Viiv Healthcare Company | $1,684.87 | 2023-2025 | Apretude, Dovato, Cabenuva |
| Abbvie INC. | $1,273.91 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $751.02 | 2022-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $597.40 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $370.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $297.45 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Otsuka America Pharmaceutical, INC. | $276.75 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Emd Serono, INC. | $261.84 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $258.89 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.57 | 2022-2025 | Caplyta |
| Lundbeck LLC | $198.99 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $167.18 | 2021-2025 | Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $130.15 | 2021-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $122.26 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $114.47 | 2024 | Spravato, Invega Sustenna, Invega Trinza |
| Janssen Biotech, INC. | $109.51 | 2023 | Symtuza |
| Napo Pharmaceuticals INC | $94.98 | 2025 | Mytesi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.84 | 2021-2023 | Jardiance |
| Axsome Therapeutics, INC. | $80.64 | 2023-2025 | Auvelity |
| Pfizer INC. | $75.22 | 2021-2024 | |
| Alkermes, INC. | $73.37 | 2023-2025 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $46.39 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $43.77 | 2021 | |
| Amgen INC. | $42.08 | 2024 | Repatha |
| Mylan Specialty L.P. | $39.89 | 2021-2022 | |
| Astellas Pharma US INC | $39.06 | 2021-2023 | Myrbetriq |
| Antares Pharma, INC. | $33.55 | 2024 | Xyosted |
| Hologic Sales and Service, LLC | $22.98 | 2025 | Aptima, Thinprep 2000 Processor |
| Abbott Laboratories | $15.55 | 2023 | Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $13.57 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $13.41 | 2023 | Trintellix |
| Grifols USA, LLC | $12.10 | 2021 | |
| Organon LLC | $10.59 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephane Counts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.